
    
      Phase 3 randomized study to compare the progression free survival of subjects with
      relapsed/refractory CTCL who receive KW-0761 versus those who receive vorinostat. Subjects
      who progress on vorinostat will be allowed to cross over to KW-0761 upon progression.
    
  